Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Banking and Pharma stocks in favor
Wed, 16 Sep 11:30 am

After opening on a firm note, the Indian Markets continued to trade positively. Sectoral indices are trading on a mixed note with stocks from the banking and pharma sectors leading the pack of gainers.

The BSE-Sensex is trading up 166 points (up 0.6%) and the NSE-Nifty is trading up 43 points (up 0.6%). The BSE Mid Cap index is trading marginally down while the BSE Small Cap index is trading down by 0.2%. The rupee is trading at 66.47 to the US dollar.

Stocks in the power space are trading on a mixed note with PTC India Ltd and Reliance Infra leading the losses. As per a leading financial daily, the Union Government is going to pump in Rs 700 bn to replace old thermal power plants. The government has firmed up plans to shut down some 11,000 mega watt (mw) of thermal power generation capacities that are at least 25 years old and build bigger plants with total capacity of at least 20,000 mw on the same tract of land. The move is expected to lead to savings of about Rs 400 bn on land acquisition and infrastructure costs.

Automobile stocks are trading mixed with TVS Motors and Hero Motocorp witnessing maximum buying interest. As per a leading financial daily, Tata Motors - owned Jaguar Land Rover (JLR) has entered the Sports Utility Vehicle (SUV) market with the launch of F-Pace model which is expected to hit the Indian market in the second half of 2016. It is also expected to hit the roads in Europe and the US in a phased rollout by early next year. The cars will be produced at JLR's 500-million pounds Solihull factory in the UK using new architecture which is more aluminum based. Presently the scrip of Tata Motors is trading flat on the BSE.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Banking and Pharma stocks in favor". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.